Pink Sheets: Starpharma Holdings Ltd (SPHRY) news stock charts
Starpharma Holdings Ltd (SPHRY/SPHRY.PK) Penny Investment Summary:
Starpharma Holdings Limited, through its subsidiaries, engages in the discovery, development, and commercialization of dendrimers for pharmaceutical and other life science applications in Australia and the United States. Its products under development include VivaGel, a vaginal microbicide for the prevention of sexually transmitted infections, such as genital herpes and HIV; and PrioFect, a transfection reagent that transfers genetic materials. The company markets its products in the form of diagnostic elements and laboratory reagents. Starpharma Holdings is based in Melbourne, Australia.STARPHARMA HOLDINGS-SPON ADR (SPHRY:Pink OTC Markets Inc - International Prime QX)
Snapshot of STARPHARMA HOLDINGS-SPON ADR (SPHRY)
|
OPEN
$6.25
|
PREVIOUS CLOSE
$6.50
|
|
|
DAY HIGH
$6.35
|
DAY LOW
$6.25
|
|
|
52 WEEK HIGH
02/22/10 - $6.70
|
52 WEEK LOW
03/17/09 - $1.20
|
|
|
MARKET CAP
150.7M
|
AVERAGE VOLUME 10 D
5.7K
|
|
|
EPS TTM
--
|
SHARES OUTSTANDING
23.7M
|
|
|
SPHRY Does Not Pay Dividends
|
P/E TTM
--
|
|
| K = Thousands M = Millions B = Billions | ||
Key developments for STARPHARMA HOLDINGS-SPON ADR (SPHRY)
Starpharma Holdings Ltd., Special/Extraordinary Shareholders Meeting, Mar 25, 2010, at 16:00 EAST - East Australian Standard GST. Location: The offices of Norton Rose, Level 15, RACV Tower, 485 Bourke Street, Melbourne, Victoria,Australia. Agenda: To grant 1,428,571 fully paid ordinary shares in the company and granted 750,000 rights to fully paid ordinary shares to Jacinth Fairley.
Starpharma Holdings Ltd. announced earnings results for first half ended Dec. 31, 2009. For the period, the company reported revenue from continuing operations of AUD 930,000 (AUD 992,000 for its first half 2009), R&D expenditure of AUD 3.03 million (AUD 6.10 million), operating loss of AUD 2.64 million (operating loss of AUD 0.99 million), a net loss of AUD 2.58 million (net loss of AUD 1.88), and a basic loss per share of AUD 0.01 (loss per share of AUD 0.01). There is discussion of the business and of the results.
Starpharma Holdings Ltd. reported earnings results for the half year to December 31, 2009. The company reported net loss of $2.6 million for the half year compared with $1.9 million in the prior corresponding half. The predominant reason for the increase in loss after tax is the impact of foreign exchange on US dollar denominated cash held. Revenue was $900,000, consisting of royalty and licence income derived from partners including Siemens Healthcare and SSL International.
Starpharma Holdings Ltd financial resources
SPHRY Competitors
| Company | Last | Change |
| Alchemia Ltd/Australia | A$0.67 AUD | -0.015 |
| Avexa Ltd | A$0.14 AUD | +0.01 |
| Bionomics Ltd | A$0.31 AUD | -0.02 |
| Chemgenex Pharmaceuticals Ltd | A$0.70 AUD | +0.015 |
| Prima Biomed Ltd | A$0.14 AUD | -0.005 |
| Market data is delayed at least 15 minutes. | ||
Industry Analysis
| Valuation | SPHRY | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 20.2x |
|
| Price/Book | 4.7x |
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | 19.3x |
|
|
SPHRY |
||
SPHRY transactions
| Type Date |
Target |
|
Private Placement
November 18, 2009 |
-- |
Pink Sheets: More Recent Financial News About Starpharma Holdings Ltd
Starpharma and Lilly Sign New Drug Delivery Collaboration for Human Pharmaceuticals
Read article
Starpharma Announces $15.6 million Capital Raising
Read article
Starpharma and Lilly Sign New Drug Delivery Collaboration for Human Pharmaceuticals
Read article
US Patent Grant Extends VivaGel(R) Coverage to 2024
Read article
Starpharma Announces $15.6 million Capital Raising
Read article